Cellectis S.A. (CLLS) shareholders
Close on Nov 17, 2026Market cap $106.36MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| AstraZeneca PLC Joint filing with AstraZeneca Holdings B.V. (44.00%) | 44,000,000 | 44.00% | 13D (active) amendment | Jan 23, 2025 |
| Caisse des Depots Joint filing with Bpifrance Participations S.A. (10.00%), EPIC Bpifrance (10.00%) and 1 more | 10,599,440 | 11.10% | 13D (active) amendment | Dec 3, 2025 |
| Bpifrance S.A. Joint filing with Bpifrance Participations S.A. (10.00%), Caisse des Depots (10.00%) and 1 more | 9,559,534 | 10.00% | 13D (active) amendment | Oct 28, 2026 |
| John B. Helmers Joint filing with Long Focus Capital Management, LLC (6.30%) | 4,487,293 | 6.30% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CLLS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| B Group, Inc. | 3,281,501 | 3.27% | $9.84M | – | 4.62% |
| Long Focus Capital Management, LLC | 2,741,853 | 2.73% | $8.23M | −2,245 | 0.21% |
| UBS Asset Management Americas Inc | 2,644,881 | 2.64% | $7.93M | −533,739 | 0.00% |
| Nomura Asset Management International Inc. | 226,875 | 0.23% | $681.00K | – | 0.00% |
| BlackRock, Inc. | 225,444 | 0.22% | $676.33K | −116,079 | 0.00% |
| Morgan Stanley | 85,455 | 0.09% | $256.37K | −1,321 | 0.00% |
| LPL Financial LLC | 84,415 | 0.08% | $253.25K | +70 | 0.00% |
| Susquehanna International Group, Llp | 50,453 | 0.05% | $151.36K | −15,489 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 40,100 | 0.04% | $120.30K | −900 | 0.00% |
| UBS Group AG | 33,926 | 0.03% | $101.78K | +4,152 | 0.00% |
| Delaney Dennis R | 24,000 | 0.02% | $72.00K | – | 0.02% |
| Rhumbline Advisers | 14,328 | 0.01% | $42.98K | −757 | 0.00% |
| XTX Topco Ltd | 12,282 | 0.01% | $36.85K | −3,987 | 0.00% |
| Harbour Investments, Inc. | 4,500 | 0.00% | $13.50K | – | 0.00% |
| National Bank Of Canada /Fi/ | 3,600 | 0.00% | $10.80K | – | 0.00% |
| Wells Fargo & Company/Mn | 3,150 | 0.00% | $9.45K | – | 0.00% |
| Royal Bank of Canada | 1,558 | 0.00% | $5.00K | New | 0.00% |
| Atlantic Union Bankshares Corp | 1,500 | 0.00% | $4.50K | – | 0.00% |
| Allworth Financial LP | 500 | 0.00% | $1.50K | – | 0.00% |
| POM Investment Strategies, LLC | 495 | 0.00% | $1.49K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 27 | 9M | 9.4% | 3 / 2 | 9 / 8 | 0M | 1M |
| Q1 2026 | 32 | 10M | 10.2% | 4 / 3 | 14 / 5 | 0M | 0M |
| Q4 2025 | 34 | 11M | 10.5% | 13 / 6 | 5 / 6 | 4M | 2M |
| Q3 2025 | 28 | 8M | 8.3% | 7 / 6 | 6 / 3 | 0M | 4M |
| Q2 2025 | 24 | 12M | 11.7% | 3 / 5 | 8 / 6 | 0M | 2M |
| Q1 2025 | 27 | 14M | 13.6% | 3 / 6 | 8 / 5 | 4M | 3M |
| Q4 2024 | 29 | 13M | 12.7% | 6 / 6 | 6 / 4 | 4M | 1M |
| Q3 2024 | 27 | 10M | 9.7% | 3 / 5 | 5 / 2 | 0M | 0M |
| Q2 2024 | 27 | 10M | 9.7% | 4 / 3 | 7 / 7 | 2M | 0M |
| Q1 2024 | 31 | 10M | 10.0% | 3 / 9 | 5 / 5 | 0M | 0M |
| Q4 2023 | 34 | 10M | 9.9% | 9 / 7 | 8 / 6 | 0M | 2M |
| Q3 2023 | 31 | 11M | 11.4% | 2 / 8 | 6 / 7 | 0M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
2 funds held CLLS in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CLLS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Nomura Healthcare Fund | 226,875 | 0.23% | $680.63K | 0.09% | Jun 30, 2026 |
| iShares Biotechnology ETF | 223,114 | 0.22% | $669.34K | 0.01% | Jun 30, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cellectis's stock actually held short. Settlement fails (shares not delivered on time) peaked at 134,431 shares on Sep 15, 2026 over the last 90 days.
See a number that looks wrong?